Evogen will collaborate with biopharmaceutical company, UCB, for further development of the new proteomics-based blood test, EvoScore START.
The test has been designed to accurately classify epileptic seizures, helping to reduce delays in treatment for some epilepsy patients and incorrect treatment for others.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
Evogen president and CEO Todd Wallach said: "Evogen aims to be the leader in neurology proteomic and genomic testing, and we believe that EvoScore START has the potential to revolutionise the diagnosis of epilepsy.
"We are accordingly thrilled to work with epilepsy leader UCB to conduct further development of this innovative biomarker-based blood test.
“We have always admired UCB's long-standing commitment to the epilepsy field and look forward to UCB's expert help in further refining this important new diagnostic tool for epilepsy patients and their healthcare providers."
The EvoScore START analyses the ratio and concentration of key protein biomarkers in a simple blood test format in order to determine the probability of an event as a seizure, with enhanced sensitivity and specificity.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataUCB neurology patient value unit head Jeff Wren said: "We believe the availability of more accurate and accessible diagnostics, like EvoScore START, may improve time to care for epilepsy patients and could deliver additional value across the broader healthcare system."
